Europe – EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17

EMA’s human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Nuvaxovid to include use in adolescents aged 12 to 17 years. The vaccine, developed by Novavax CZ, a.s., is already approved for use in adults aged 18 and above.

The use of the vaccine in adolescents is the same as in adults, with two injections given in a muscle, three weeks apart.

A main study including over 2,200 children aged 12 to 17 years is being carried out in accordance with the paediatric investigation plan (PIP) for the vaccine, which was agreed by EMA’s Paediatric Committee (PDCO)…